Summary : Better treatment for conditions experienced by individuals who were exposed to alcohol before birth The National Institute for Health and…
Pharmanews
-
-
CompaniesCovid DrugsPfizer
Pfizer and BioNTech aubmit for U.S. Emergency Use Authorization of an additional booster dose of their COVID-19 vaccine for older adults
by adminby adminSummary : Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the companies have submitted an application to the U.S. Food…
-
Summary : Endo Pharmaceuticals and Endo Health Solutions, makers of Percocet, Opana, and Percodan, have settled with the State of Florida for…
-
Summary : The p53 protein protects our cells from cancer and is an interesting target for cancer treatments. The problem is, however,…
-
CompaniesMerck & CoMerger / Acquisition
Merck & Co pens $340m pain drug deal with KCL and Wellcome
by adminby adminSummary Merck & Co has announced a deal with King’s College London (KCL) and Wellcome to investigate a new class of painkillers…
-
AstraZenecaCompaniesMerck & CoRegulatoryU.S FDA
AZ, Merck get FDA okay for Lynparza as adjuvant breast cancer therapy
by adminby adminSummary : The FDA has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant or neoadjuvant treatment for breast cancer, extending…
-
AstraZenecaRegulatoryU.S FDA
FDA says no to AZ’s Fasenra for nasal polyp indication
by adminby adminSummary : AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic…
-
Pharma Science & Research
Mutations leading to omicron variant did not enable virus to fully escape immune system
by adminby adminPeople who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19,…
-
Pharma Science & Research
Stealth nanomedicines combat cancer and cut toxic effects of chemo
by adminby adminSynopsis : Nanomedicines – typically drugs hidden within nanoscopic fatty membranes (‘liposomes’) – have potential to transform chemotherapy treatments, improving drug delivery…
-
Pharma Science & ResearchSanofi Inc.
Nirsevimab first potential immunisation to protect against RSV in infants
by adminby adminSynopsis : Nirsevimab has the potential to offer RSV protection for all infants, with a single dose showing 74.5 percent efficacy in…